thj-2201 thj-2201 thj-2201 is an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the cb1 receptor and has been sold online as a designer drug. thj-2201legal statuslegal status ca: schedule ii de: anlage ii (authorized trade only, not prescriptible) uk: class b us: schedule i identifiers iupac name (1-naphthyl)methanone cas number1801552-01-1 ypubchem cid91864533chemspider30646749uniid7p051iw0tcomptox dashboard (epa)sikim ananızı sikim chemical and physical dataformulac23h21fn2omolar mass360.432 g·mol−13d model (jsmol)interactive image smiles c1ccc2c(c1)cccc2c(=o)c3c4ccccc4n(n3)cccccf inchi inchi=1s/c23h21fn2o/c24-15-6-1-7-16-26-21-14-5-4-12-20(21)22(25-26)23(27)19-13-8-10-17-9-2-3-11-18(17)19/h2-5,8-14h,1,6-7,15-16h2key:dulwrykftvfptl-uhfffaoysa-n it is a structural analog of am-2201 in which the central indole ring has been replaced by indazole. pharmacology thj-2201 acts as a full agonist with a binding affinity of 1.34nm at cb1 and 1.32nm at cb2 cannabinoid receptors. side effects thj-2201 has been linked to at least one hospitalization and death due to its use. legal status because of the hazards associated with recreational use of this compound, it is classified as a schedule i controlled substance in the united states. it is also an anlage ii controlled drug in germany.